Executive Profiles

Executive Roundtable

Leadership

Press Releases

Corporate Communications

Healthcare Access

Patient Education

Telehealth

Direct-to-Consumer

Funding

Partnerships

Emerging Biopharma

Finance

Industry Trends

IR Licensing and Partnerships

Patient Access

Pricing

Strategy

Market Access

Clinical Data

Patient Advocacy

Pharmacovigilance

Medical Affairs

R&D/Clinical Trials

Supply Chain

Sustainability

Technology

Operations

DE&I

Patient Engagement

Global

Legal

Regulatory

Campaigns

DTC Marketing

Medical Education

Sales Effectiveness

Sales & Marketing

News

Academy

Multimedia

Editorial Podcasts

Editorial Videos

Peer Exchange

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Partner Perspectives

Resources

Content Engagement Hubs

E-Books

Events

Webcasts

Whitepapers

Subscribe

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

About

Advertise

Contact Us

Editorial Board

Editorial Submission Guidelines

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Executive - Leadership, Strategy & Market Access

LinkedIN

Instagram

Facebook

Threads

Bluesky

Spotlight

Latest Executive Roundtables

Asembia 2025 

Topic

Sales and Marketing

1rem

The new funding is expected to fuel clinical progress for Alchemab’s muscle atrophy candidate and expand its AI-driven pipeline targeting immune and neurological diseases.

Alchemab Advances AI-Enabled Antibody Platform with Phase I Trial, $32 Million Financing Boost

The deal gives Avadel global rights to develop and market valiloxybate for narcolepsy and idiopathic hypersomnia, with a once-at-bedtime, sodium-free formulation designed to improve patient convenience and outcomes.

Avadel Partners with XWPharma to Commercialize Sleep Medication 

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as the companies explore a novel drug candidate for severe neurological disorders.

Novartis, BioArctic Reach Deal to Develop BrainTransporter Therapy for Neurodegeneration

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward regulatory approval and patient access.

Boehringer Ingelheim, AnGes Ink Deal to Produce Next-Generation PAD Gene Therapy

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing treatment options remain limited.

Skyhawk Therapeutics, Merck KGaA Strike Multi-Billion Dollar Deal to Advance RNA Therapies in Neurology

Advancing Innovative Medicines Through Global Regulatory and Academic Partnerships

, Rob Abbott, CEO of ISPOR, discussed how health economics and outcomes research (HEOR) is transforming the way health systems and governments around the world address rising drug prices. Abbott highlighted the growing importance of real-world evidence, patient-centered approaches, and artificial intelligence in shaping value-based healthcare decisions. He also emphasized the critical role of cross-sector collaboration among regulators, payers, academia, and industry in advancing evidence-based policies and improving patient access to innovative therapies.

Pharmaceutical Executive: What collaborations or partnerships are most critical right now—across government, academia, or industry—to advance evidence-based health policy and access globally?

Let me start with ISPOR, because it’s central to how I think about this question. Healthcare is incredibly complex—it’s an ecosystem with many stakeholders, and we have to understand how those players interact.

ISPOR is the global society for health economics and outcomes research, with more than 20,000 members in over 100 countries. Our members represent academia, government, patient groups, NGOs such as the Institute for Clinical and Economic Review in the United States, as well as investors and payers. What’s most important is the dynamic interaction among these groups.

We’ve found it crucial to bring regulators, payers, and health technology assessment (HTA) agencies together. In fact, we’re launching a pilot project in Europe this fall to do exactly that. We chose Europe intentionally, given that the European Union’s new HTA regulation—officially in effect this year—has the potential to be a real game changer for patient access to innovative medicines.

The key is not to operate in silos. Collaboration across the ecosystem is essential. At ISPOR, we are working closely with the FDA, the European Medicines Agency, and leading academic institutions worldwide. These partnerships ensure we have access to cutting-edge thought leadership on where healthcare is heading, and how health economics and outcomes research can guide that path.

At the end of the day, collaboration and cooperation are vital if we want to navigate the maze of complexity, costs, and challenges in healthcare.

 Health economics and outcomes research (HEOR) is increasingly shaping how health systems and governments address rising drug prices. HEOR integrates clinical trial results, real-world data, patient experiences, and economic analysis to evaluate medical interventions. By assessing a treatment’s cost-effectiveness and real-world value, HEOR informs value-based pricing and decision-making, going beyond traditional clinical trial data to determine how drugs perform in everyday patient care.

A key trend highlighted in ISPOR’s 2024–2025 Top 10 Trends report is the growing importance of real-world evidence. Unlike clinical trials, real-world evidence captures patient outcomes, side effects, and overall cost-effectiveness after drugs enter the market, making it critical for both policy and clinical decisions. Another transformative trend is the accelerated adoption of artificial intelligence (AI) and digital health tools. AI is being used to synthesize literature, analyze complex data sets, and tailor treatment protocols efficiently. However, experts caution that while AI offers significant potential, human oversight remains essential to ensure patient-centered care.

From a global perspective, US healthcare excels in certain areas, such as cancer screening, vaccination rates, and advanced medical technology, but faces challenges including high per-capita costs, lack of universal coverage, and suboptimal outcomes in chronic disease and life expectancy. These issues highlight the universal challenge of managing rising costs amid increasing complexity.

Collaboration across government, academia, and industry is critical to advance evidence-based health policy and patient access. Organizations like ISPOR, with its global membership spanning regulators, payers, patient organizations, and academics, are fostering these partnerships. Initiatives, such as pilot projects aligning regulators and health technology assessment agencies in Europe, illustrate how coordinated efforts can improve patient access to innovative therapies while navigating the complexities of cost, efficacy, and healthcare delivery.

Overall, HEOR, real-world evidence, AI, and multi-stakeholder collaboration are central to shaping efficient, patient-centered, and cost-conscious healthcare systems worldwide.

Videos

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

Video Series

Partnerships

Latest News